Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances enhance insulin release and reduce gluca

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing differences in